Compare ClearPoint Neuro Inc (CLPT) vs NIO Inc. (NIO) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

NIO trades at $4.93, up 3.14% today, but remains in a bearish technical trend with negative cash flows and persistent losses despite revenue growth to $87.49 billion in 2025. The company beat EPS estimates for three consecutive quarters, and June 2026 deliveries surged 62.9% year-over-year, indicating strong operational momentum. However, net income margin improved to -17.8% in 2025 but remains deep in negative territory, with a high debt load and substantial cash burn from operations.

Outlook is mixed: bullish delivery growth and analyst upgrades (Goldman Sachs to Buy, target $7) contrast with profitability risks and competitive EV market pressures. Investment appeal hinges on margin improvement and sustainable cash flow generation, while key risks include execution challenges, macroeconomic headwinds, and reliance on financing amid negative equity.